Achilles Therapeutics plc stock is up 47.78% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 February’s closed higher than January.
Achilles Therapeutics Plc develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; THETIS, a product candidate in clinical trials for use of metastatic or recurrent melanoma. Achilles is headquartered in London, the United Kingdom.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!